Checkpoint Inhibitors and Their Application in Breast Cancer

Davide Bedognetti, Cristina Maccalli, Salha B.J. Al Bader, Francesco M. Marincola, Barbara Seliger

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Immune checkpoints are crucial for the maintenance of self-tolerance and for the modulation of immune responses in order to minimize tissue damage. Tumor cells take advantage of these mechanisms to evade immune recognition. A significant proportion of tumors, including breast cancers, can express co-inhibitory molecules that are important formediating the escape from T cell-mediated immune surveillance. The interaction of inhibitory receptors with their ligands can be blocked by specific molecules. Monoclonal antibodies (mAbs) directed against the cytotoxic T lymphocyte-associated antigen-4 (CTLA4) and, more recently, against the programmed cell death protein 1 (PD1), have been approved for the therapy of melanoma (anti-CTLA4 and anti-PD1 mAbs) and non-small cell lung cancer (anti-PD1 mAbs). Moreover, inhibition of PD1 signaling has shown extremely promising signs of activity in breast cancer. An increasing number of molecules directed against other immune checkpoints are currently under clinical development. In this review, we summarize the evidence supporting the implementation of checkpoint inhibition in breast cancer by reviewing in detail data on PD-L1 expression and its regulation. In addition, opportunities to boost anti-tumor immunity in breast cancer with checkpoint inhibitor-based immunotherapies alone and in combination with other treatment options will be discussed.

Original languageEnglish
Pages (from-to)108-115
Number of pages8
JournalBreast Care
Volume11
Issue number2
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint

CTLA-4 Antigen
Breast Neoplasms
Monoclonal Antibodies
Programmed Cell Death 1 Receptor
Self Tolerance
Neoplasms
Non-Small Cell Lung Carcinoma
Immunotherapy
Immunity
Melanoma
Ligands
T-Lymphocytes
Therapeutics
Thomsen-Friedenreich antibodies

Keywords

  • Antibody therapy
  • Biomarker
  • Biomarker
  • Breast cancer
  • Breast cancer
  • Immune system
  • Immune system
  • Immunomodulation
  • Immunomodulation
  • Immunotherapy
  • Immunotherapy
  • Tumor marker
  • Tumor markerAntibody therapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Checkpoint Inhibitors and Their Application in Breast Cancer. / Bedognetti, Davide; Maccalli, Cristina; Al Bader, Salha B.J.; Marincola, Francesco M.; Seliger, Barbara.

In: Breast Care, Vol. 11, No. 2, 01.04.2016, p. 108-115.

Research output: Contribution to journalReview article

Bedognetti, Davide ; Maccalli, Cristina ; Al Bader, Salha B.J. ; Marincola, Francesco M. ; Seliger, Barbara. / Checkpoint Inhibitors and Their Application in Breast Cancer. In: Breast Care. 2016 ; Vol. 11, No. 2. pp. 108-115.
@article{db844c550e0a44079a2149f6b87fe98e,
title = "Checkpoint Inhibitors and Their Application in Breast Cancer",
abstract = "Immune checkpoints are crucial for the maintenance of self-tolerance and for the modulation of immune responses in order to minimize tissue damage. Tumor cells take advantage of these mechanisms to evade immune recognition. A significant proportion of tumors, including breast cancers, can express co-inhibitory molecules that are important formediating the escape from T cell-mediated immune surveillance. The interaction of inhibitory receptors with their ligands can be blocked by specific molecules. Monoclonal antibodies (mAbs) directed against the cytotoxic T lymphocyte-associated antigen-4 (CTLA4) and, more recently, against the programmed cell death protein 1 (PD1), have been approved for the therapy of melanoma (anti-CTLA4 and anti-PD1 mAbs) and non-small cell lung cancer (anti-PD1 mAbs). Moreover, inhibition of PD1 signaling has shown extremely promising signs of activity in breast cancer. An increasing number of molecules directed against other immune checkpoints are currently under clinical development. In this review, we summarize the evidence supporting the implementation of checkpoint inhibition in breast cancer by reviewing in detail data on PD-L1 expression and its regulation. In addition, opportunities to boost anti-tumor immunity in breast cancer with checkpoint inhibitor-based immunotherapies alone and in combination with other treatment options will be discussed.",
keywords = "Antibody therapy, Biomarker, Biomarker, Breast cancer, Breast cancer, Immune system, Immune system, Immunomodulation, Immunomodulation, Immunotherapy, Immunotherapy, Tumor marker, Tumor markerAntibody therapy",
author = "Davide Bedognetti and Cristina Maccalli and {Al Bader}, {Salha B.J.} and Marincola, {Francesco M.} and Barbara Seliger",
year = "2016",
month = "4",
day = "1",
doi = "10.1159/000445335",
language = "English",
volume = "11",
pages = "108--115",
journal = "Breast Care",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Checkpoint Inhibitors and Their Application in Breast Cancer

AU - Bedognetti, Davide

AU - Maccalli, Cristina

AU - Al Bader, Salha B.J.

AU - Marincola, Francesco M.

AU - Seliger, Barbara

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Immune checkpoints are crucial for the maintenance of self-tolerance and for the modulation of immune responses in order to minimize tissue damage. Tumor cells take advantage of these mechanisms to evade immune recognition. A significant proportion of tumors, including breast cancers, can express co-inhibitory molecules that are important formediating the escape from T cell-mediated immune surveillance. The interaction of inhibitory receptors with their ligands can be blocked by specific molecules. Monoclonal antibodies (mAbs) directed against the cytotoxic T lymphocyte-associated antigen-4 (CTLA4) and, more recently, against the programmed cell death protein 1 (PD1), have been approved for the therapy of melanoma (anti-CTLA4 and anti-PD1 mAbs) and non-small cell lung cancer (anti-PD1 mAbs). Moreover, inhibition of PD1 signaling has shown extremely promising signs of activity in breast cancer. An increasing number of molecules directed against other immune checkpoints are currently under clinical development. In this review, we summarize the evidence supporting the implementation of checkpoint inhibition in breast cancer by reviewing in detail data on PD-L1 expression and its regulation. In addition, opportunities to boost anti-tumor immunity in breast cancer with checkpoint inhibitor-based immunotherapies alone and in combination with other treatment options will be discussed.

AB - Immune checkpoints are crucial for the maintenance of self-tolerance and for the modulation of immune responses in order to minimize tissue damage. Tumor cells take advantage of these mechanisms to evade immune recognition. A significant proportion of tumors, including breast cancers, can express co-inhibitory molecules that are important formediating the escape from T cell-mediated immune surveillance. The interaction of inhibitory receptors with their ligands can be blocked by specific molecules. Monoclonal antibodies (mAbs) directed against the cytotoxic T lymphocyte-associated antigen-4 (CTLA4) and, more recently, against the programmed cell death protein 1 (PD1), have been approved for the therapy of melanoma (anti-CTLA4 and anti-PD1 mAbs) and non-small cell lung cancer (anti-PD1 mAbs). Moreover, inhibition of PD1 signaling has shown extremely promising signs of activity in breast cancer. An increasing number of molecules directed against other immune checkpoints are currently under clinical development. In this review, we summarize the evidence supporting the implementation of checkpoint inhibition in breast cancer by reviewing in detail data on PD-L1 expression and its regulation. In addition, opportunities to boost anti-tumor immunity in breast cancer with checkpoint inhibitor-based immunotherapies alone and in combination with other treatment options will be discussed.

KW - Antibody therapy

KW - Biomarker

KW - Biomarker

KW - Breast cancer

KW - Breast cancer

KW - Immune system

KW - Immune system

KW - Immunomodulation

KW - Immunomodulation

KW - Immunotherapy

KW - Immunotherapy

KW - Tumor marker

KW - Tumor markerAntibody therapy

UR - http://www.scopus.com/inward/record.url?scp=84969179545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969179545&partnerID=8YFLogxK

U2 - 10.1159/000445335

DO - 10.1159/000445335

M3 - Review article

VL - 11

SP - 108

EP - 115

JO - Breast Care

JF - Breast Care

SN - 1661-3791

IS - 2

ER -